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Background: Chronic, low-grade inflammation and declining physical function are hall-
marks of the aging process. However, previous attempts to correlate individual inflamma-
tory biomarkers with physical performance in older people have produced mixed results.
Given the complexity of the inflammatory response, the simultaneous analysis of an array
of inflammatory mediators may provide more insights into the relationship between inflam-
mation and age-related physical function decline. This study was designed to explore the
association between a panel of inflammatory markers and physical performance in older
adults through a multivariate statistical approach.
Methods: Community-dwelling older persons were categorized into “normal walkers”
(NWs; n=27) or “slow walkers” (SWs; n=11) groups using 0.8 m s−1 as the 4-m gait
speed cutoff. A panel of 14 circulating inflammatory biomarkers was assayed by multiplex
analysis. Partial least squares-discriminant analysis (PLS-DA) was used to identify patterns
of inflammatory mediators associated with gait speed categories.
Results:The optimal complexity of the PLS-DA model was found to be five latent variables.
The proportion of correct classification was 88.9% for NW subjects (74.1% in cross-
validation) and 90.9% for SW individuals (81.8% in cross-validation). Discriminant biomark-
ers in the model were interleukin 8, myeloperoxidase, and tumor necrosis factor alpha (all
higher in the SW group), and P-selectin, interferon gamma, and granulocyte–macrophage
colony-stimulating factor (all higher in the NW group).
Conclusion: Distinct profiles of circulating inflammatory biomarkers characterize older sub-
jects with different levels of physical performance. The dissection of these patterns may
provide novel insights into the role played by inflammation in the disabling cascade and
possible new targets for interventions.
Keywords: aging, gait speed, inflammaging, cytokines, disability, interleukin, immune senescence, multiplex assay
INTRODUCTION
Among the host of functional and structural changes entailed by
the aging process, physical function decline and chronic, low-grade
inflammation represent pervasive features (1, 2).
Over the last decades, there has been increasing recognition
of the importance of physical function assessment in advanced
age, both as a central component of clinical evaluation and a spe-
cific outcome for interventions (3). Walk speed at usual pace over
4 m, hereby referred to as gait speed, is an inexpensive, objec-
tive, and easy to interpret test to assess physical performance in
the elderly (4). Slow gait speed has indeed been associated with
clinical and subclinical conditions (5, 6), and is able to predict
several health-related events apparently extraneous to physical
function (e.g., incident cognitive impairment, hospitalization, sur-
gical complications, institutionalization, and mortality) (7–10).
As such, gait speed is advocated as an additional “vital sign”
to be included in the routine clinical assessment of geriatric
patients (4, 11).
The chronic, low-grade inflammatory status that accompa-
nies aging results from an imbalance between pro- and anti-
inflammatory networks, in the absence of overt infections (“ster-
ile” inflammation) (2). This phenomenon, also termed “inflam-
maging,” explains several traits of the aging phenotype and is
a major risk factor for morbidity and mortality (12). Indeed,
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inflammaging entails several cytokines, molecular pathways, effec-
tor cells, and tissue responses that are shared across a multitude of
age-related conditions (13).
Specific circulating inflammatory markers have been associ-
ated with adverse health outcomes in older persons. For instance,
elevated serum levels of interleukin (IL) 6, tumor necrosis fac-
tor alpha (TNF-α), and C-reactive protein (CRP) have been
linked with poor function and mobility status (14–18). This
evidence would support the assessment of inflammatory bio-
markers in the clinical evaluation of elderly patients. Notwith-
standing, measurements of inflammatory mediators have not
yet been incorporated into standard clinical practice, partly
because there is not a “gold standard” inflammatory measure-
ment that reliably predicts incident adverse outcomes in older
adults (19). This, in turn, is due to the fact that the effects
of inflammation on health outcomes have been inferred mostly
through the analysis of single biomarkers. However, these medi-
ators act in a complex and coordinated network in which their
functions may be modified, replaced, or modulated by other
cytokines. Yet, there have been only few attempts to develop
a comprehensive study of inflammatory markers and aggre-
gate biologically informed measures to maximize their predictive
validity (20–23).
In the present study, we hypothesized that specific patterns of
circulating inflammatory markers would characterize elderly indi-
viduals with varying levels of physical performance. To address
this research question, an array of inflammatory mediators was
assayed simultaneously in blood samples of community-living
older adults. Multivariate statistical models were constructed to
explore the relationship between systemic inflammatory profiles
and physical function.
MATERIALS AND METHODS
PARTICIPANTS
Participants were community-dwelling men and women aged
70 years or older. Recruitment of participants was coordinated
by the Recruitment Core of the University of Florida Claude D.
Pepper Older Americans Independence Center, as detailed else-
where (24–26). Recruitment strategies included media articles,
direct mailings, newspaper announcements, and presentations to
community groups.
A set of eligibility criteria was chosen to minimize the possi-
ble confounding effect of comorbid conditions, medications, or
lifestyle habits on the relationship between inflammatory profiles
and physical performance. Briefly, subjects were not included if
presenting with any of the following characteristics: smoking in
prior 12 months; engagement in regular physical exercise; history
of drug or alcohol abuse; active treatment for cancer or cancer
in the past three years; heart failure New York Heart Association
class III–IV; stroke with upper and/or lower extremity involve-
ment; Parkinson’s disease or other neurological disorders likely
to interfere with physical function; major psychiatric illnesses;
peripheral vascular disease Lériche–Fontaine stage 3–4; history of
life-threatening cardiac arrhythmias; cognitive impairment (i.e.,
Mini Mental State Examination score ≤21); renal disease requir-
ing dialysis; lung disease requiring steroids; chronic viral diseases
(e.g., hepatitis B and C, HIV); lower extremity amputation; severe
knee, or hip osteoarthritis limiting mobility; diabetes with visual,
vascular, or neuropathic complications; inflammatory diseases
(e.g., rheumatoid arthritis, vasculitis, autoimmune disorders, and
inflammatory bowel disease); taking growth hormone, estrogen
replacement, testosterone, anticoagulants, steroids, non-steroidal
anti-inflammatory drugs on a regular basis; severe obesity [i.e.,
body mass index (BMI) ≥35]; underweight (i.e., BMI ≤18.5);
active weight loss >5 kg in prior 3 months; life-threatening ill-
nesses with an estimated life expectancy <1 year. Subjects on
statin treatment were asked to refrain from drug administra-
tion 1 month prior to blood drawn upon their general practi-
tioner’s approval. Prior to enrollment in the study, all partic-
ipants provided written informed consent. The study protocol
was approved by the University of Florida’s Institutional Review
Board.
ASSESSMENT OF PHYSICAL PERFORMANCE
The physical performance status of participants was assessed by
measuring gait speed over a 4-m course at the person’s usual pace.
The faster of two trials (meters per second) was used for the analy-
sis. Physical performance testing was conducted at the study center
by trained personnel not involved in the investigation. As shown
by Guralnik et al. (27), gait speed provides an excellent estimate of
lower extremity function and possesses a predictive power for inci-
dent disability comparable to composite tools, such as the short
physical performance battery (SPPB) (28).
For the purpose of the study, subjects were categorized into
slow (SW) or normal walker (NW) groups, using 0.8 m s−1 as
the cutoff. This threshold was selected based on the evidence that
older people walking slower than 0.8 m s−1 are at especially high
risk of experiencing adverse health-related events, including dis-
ability, cognitive impairment, morbidity, institutionalization, falls,
and mortality (8–10).
BLOOD COLLECTION AND PROCESSING
Blood samples were obtained in the morning by venipuncture
of the median cubital vein after overnight fasting, using com-
mercial collection tubes (BD Medical, Franklin Lakes, NJ, USA).
For serum extraction, samples were left at room temperature
for 20 min and subsequently centrifuged at 1,000× g for 10 min
at 4°C. For plasma separation, samples were collected in EDTA
tubes and immediately centrifuged at 1,000× g for 10 min at
4°C. Serum and plasma were aliquoted and stored at −80°C until
analyses.
MULTIPLEXED IMMUNOASSAY FOR THE QUANTIFICATION OF
INFLAMMATORY MARKERS
A panel of 14 inflammatory markers, growth factors, and vas-
cular adhesion molecules, related to systemic and/or vascular
inflammation, was measured via a multiplex, magnetic bead-based
immunoassay (MILLIPLEX® map; EMD Millipore, Billerica, MA,
USA). Analytes were assayed in the serum by the MILLIPLEX®
map High Sensitivity Human Cytokine Kit Multiplex Assay (Cat.
# HSCYTMAG-60SK) and in the plasma by the MILLIPLEX®map
Human Cardiovascular Disease Magnetic Bead Panel 2 – Car-
diovascular Disease Multiplex Assay (Cat. # HCVD2MAG-67K).
The choice of the analytes was based on previous evidence of
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their possible involvement in the aging process and the disabling
cascade as well as commercial availability. Assays were performed
according to the manufacturer’s instructions, except that sam-
ples were run in triplicate. The multiplex immunoassay panels
were analyzed on a MILLIPLEX® Analyzer 3.1 xPONENT Sys-
tem (Luminex® 200™) and data analysis performed through the
MILLIPLEX® Analyst software. The inter-assay coefficient of vari-
ation was <5% for the high sensitivity human cytokine kit mul-
tiplex assay and <15% for the cardiovascular disease multiplex
assay.
STATISTICAL ANALYSIS
All analyses were performed using in-house routines running
under Matlab R2011b environment (The MathWorks, Natick,
MA, USA).
Descriptive statistics
Differences in demographic, anthropometric, clinical, and func-
tional characteristics according to gait speed categories were
assessed via the Mann–Whitney U test andχ2 test, for continuous
and categorical variables, respectively. Both tests were two-sided,
with statistical significance set at p< 0.05.
Partial least squares-discriminant analysis of gait speed categories
vs. circulating inflammatory markers
The relationship between gait speed categories and patterns of
circulating inflammatory biomarkers was explored by construct-
ing and validating a predictive classification model. The approach
chosen for the present study was based on Partial least squares-
discriminant analysis (PLS-DA) (29), due to its versatility and
ability to deal with highly correlated predictors. Briefly, PLS-DA
is a classification method based on the PLS regression algorithm
(30); thus, in order to introduce the former, it is necessary to
describe the latter.
Designating with X the matrix of predictors (inflammatory
markers) and Y the matrix of responses (gait speed categories),
the aim of PLS regression was to find the optimal set of coefficients
B relating X to Y, according to:
Y = XB (1)
Partial least squares regression is, therefore, a linear regression
model, but differs from the classical multiple linear regression
approach in that only the relevant part of the information present
in the X matrix is used for the prediction of Y. Indeed, PLS model-
ing involves projecting the X data (which lie onto a p-dimensional
space, p being the number of measured variables) onto a lower-
dimensional subspace of so-called latent variables (LVs). LVs are
defined as those directions in space where there is the maxi-
mum covariance between X and Y blocks. The representation
of data onto the reduced subspace of LVs is captured by the scores
matrix T :
T = XR (2)
R being the projection matrix. It is then the T matrix that is
used to predict Y according to:
Y = T QT (3)
where Q is a set of coefficients called Y -loadings. By combining R
and Q, the regression coefficients B defined in Eq. (1) are obtained:
B = RQT (4)
Since the scores matrix is low-dimensional and its columns are
orthogonal, PLS allows building regression models also for so-
called “ill-conditioned” problems, i.e., those cases in which the
number of measured variables is larger than the number of indi-
viduals and/or the measured variables are highly correlated with
each other.
The PLS-DA algorithm was designed to take advantage of these
characteristics and to cope with classification problems, for which
other methods, such as linear discriminant analysis, suffer the same
drawbacks of classical multiple linear regression approaches. To
this purpose, the classification problem has to be stated in terms
of regression, which is accomplished by means of a dummy-coded
vector y that accounts for class-belonging. For each participant,
the value of y was set to 1 if he/she belonged to the NW group and
0 if he/she belonged to the SW class. A standard PLS model was
then calculated between the X matrix of experimental variables
(inflammatory markers) and the dummy-coded vector codifying
for class-belonging. The classification was eventually carried out
on the basis of the values of y predicted by the algorithm. Since
the two categories of gait speed were coded as 0 and 1, if the pre-
dicted y for an individual was greater than 0.5, he/she would be
classified as NW. Conversely, for predicted y values lower than this
threshold, he/she would be classified as SW.
Once the model was calculated, information about the exper-
imental variables more important in the discrimination was
obtained by inspecting the so-called variable importance in pro-
jection (VIP) indices (31). VIP scores indicate the contribution of
each of the measured variables to the PLS model and are scaled
so that a “greater than 1” rule can be used to assess statistical
significance.
Validation of the PLS-DA model
For any statistical model to be reliable, the calibration stage should
always be accompanied by a careful validation of its results. The
choice of proper validation becomes even more relevant when
the phase of model building involves the selection of the opti-
mal value of some adjustable parameters (as it occurs in the case
of PLS-DA, where the number of LVs has to be set). Since the
optimal values of the parameters are typically chosen as the ones
that minimize some kind of error measurement in a dataset (pos-
sibly treated as unknowns by the model), this same set of data
cannot be used also to evaluate the final model performance (as
it would lead to overoptimistic results). When many samples are
available, this translates into the necessity of having three sets of
data: the calibration set for model building, the internal valida-
tion set for the selection of model parameters, and the external
validation set (or test set) for the final validation of model per-
formance. However, in cases such as the one of the present study,
where the number of participants would not allow extracting three
representative sets, re-sampling strategies may be used. In partic-
ular, the so-called double cross-validation strategy was adopted
(32). Double cross-validation operates by randomly extracting
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from the available number of samples a small subset to consti-
tute an external validation set. The remaining samples are then
divided into a certain number of cancelation groups, like in stan-
dard cross-validation, to estimate the optimal model complexity.
The optimal model on this subset of data is subsequently validated
on the external validation subset. The whole procedure is repeated
a suitable number of iterations to obtain a good representativeness
and the final results are averaged.
In order to rule out any possibility of chance correlation, the
average results obtained from the double cross-validation pro-
cedure were further compared with the results of permutation
tests. These tests are used to obtain an empirical distribution of
the classification figures of merit under the null hypothesis (i.e.,
under the assumption that no discrimination exists between the
two classes), and are carried out by repeating the whole modeling
stage on datasets for which the class labels are randomly permuted.
In the present study, permutation tests involved 1,000 randomiza-
tions. Three figures of merit were considered: (1) the number of
misclassifications (NMC), (2) the area under the receiver oper-
ating characteristic (ROC) curve (AUROC), and (3) the value
of the discriminant Q2 (DQ2) (33). NMC is the most intuitive
of all diagnostic statistics as it simply indicates the number of
samples (or participants, as in the present investigation), which
are wrongly classified by the model. AUROC is a figure of merit
borrowed from signal processing and is particularly useful to
characterize binary classifiers. Its values range between 1 (perfect
classification) and 0 (no discrimination). DQ2 was introduced
by Westerhuis et al. (34) as a modification of the standard Q2
(R2 in cross-validation) to cope with the peculiarities of classifica-
tion problems addressed by regression methods. Like its regression
analog, DQ2 assumes its highest values in the case of a perfect dis-
crimination between classes. Differently from standard Q2, DQ2
can also be negative (i.e., it is not bound to the 0–1 range of
values).
RESULTS
DESCRIPTIVE CHARACTERISTICS OF THE STUDY SAMPLE
A total of 38 community-dwelling older adults were recruited for
the study, 27 NWs and 11 SWs. Demographic, anthropometric,
functional, and clinical characteristics of participants according
to gait speed categories are shown in Table 1. SW subjects were
significantly older than NWs (p= 0.0118). The average gait speed
was 0.62 m s−1 (±0.08 SD) in the SW group and 1.10 m s−1 (±0.18
SD) among NW participants (p< 0.0001). No differences between
groups were observed with regard to gender or ethnicity distrib-
ution, BMI, and number of comorbid conditions or medications.
The average concentrations of circulating inflammatory markers
in the two gait speed groups are reported in Table 2.
PARTICIPANT CLASSIFICATION ACCORDING TO PLS-DA
Given the different age distribution of participants belonging to
the two gait speed categories, a preliminary analysis was con-
ducted to rule out the existence of a relationship between inflam-
matory markers and age. To this purpose, a PLS model relat-
ing these variables was built and validated. The optimal model,
which included five LVs and accounted for 82.8% of the X
and 46.8% of the Y variance, showed very poor performance
Table 1 | Descriptive characteristics of the study population according
to gait speed categories.
Gait speed categories p-value
Normal walkers
(n=27)
Slow walkers
(n=11)
Age, years (mean±SD) 76.4±5.5 81.5±4.9 0.0118
Gender (female), n (%) 10 (37.0) 5 (45.5) 0.6300
Ethnicity, n (%)
Caucasian 26 11 0.5179
Afro-American 0 0
Other 1 0
BMI (mean±SD) 26.7±3.7 28.2±4.0 0.2952
Number of medications
(mean±SD)
3.0±2.9 4.0±3.0 0.3893
Comorbiditiesa (mean±SD) 0.74±0.98 1.27±1.56 0.2122
Gait speed, m s−1
(mean±SD)
1.10±0.18 0.62±0.08 0.0001
BMI, body mass index; SD, standard deviation.
aIncludes coronary artery disease, hypertension, prior stroke, peripheral vascu-
lar disease, osteoarthritis, chronic obstructive pulmonary disease, and diabetes
mellitus.
both in calibration [Root Mean Squared Error (RMSE)= 4.2;
R2= 0.48] and in sixfold cross-validation [RMSE cross-validation
(RMSECV)= 6.2; Q2= 0.01]. This observation indicates that, in
our study sample, circulating levels of inflammatory mediators are
not significantly influenced by age.
In order to verify the existence of specific patterns of inflam-
matory markers in participants with varying gait speed perfor-
mance, a PLS-DA classification model was constructed and vali-
dated. The optimal PLS-DA model was built using five LVs that
accounted for more than 75.4% of the variance originally present
in the X block. As indicated by the double cross-validation pro-
cedure, the model allowed to correctly predict the gait speed
category in 89.9% of participants in the calibration phase (90.9%
for NWs and 88.9% for SWs), 77.9% in the internal validation
stage (81.1% for NWs and 74.1% for SWs), and 71.1% in the
external validation (73.7% for NWs and 69.8% for SWs). The
classification ability of the model is also evident by inspecting
the projection of participants onto the space spanned by the
first three LVs of the PLS-DA model (Figure 1), which shows a
clear separation between subjects assigned to the two gait speed
groups.
To further validate the classification model and rule out the
possibility of chance correlations, the results of the double cross-
validation procedure were compared with the distributions of
specific figures of merit under the null hypothesis. The distribution
of NMC,AUROC, and DQ2 under their respective null hypothesis,
as estimated by the permutation tests, is reported in Figure 2. The
corresponding values obtained by the PLS-DA model on unper-
muted data, as evaluated by the double cross-validation procedure,
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Table 2 | Serum or plasma concentration of inflammatory biomarkers
according to gait speed categories.
Gait speed categories
Normal walkers
(n=27)
Slow walkers
(n=11)
mean±SD mean±SD
GM-CSF, pg mL−1a 1.99±4.09 0.46±0.71
IFN-γ, pg mL−1a 6.04±12.28 0.90±1.50
IL1β, pg mL−1a 0.59±1.14 0.13±0.12
IL5, pg mL−1a 0.92±1.79 0.61±0.97
IL6, pg mL−1a 2.90±3.78 3.93±4.39
IL8, pg mL−1a 3.70±1.67 4.34±1.46
IL10, pg mL−1a 37.00±58.31 27.02±33.79
IL12(p70), pg mL−1a 4.21±13.49 10.29±31.44
IL13, pg mL−1a 5.25±10.56 3.90±8.65
TNF-α, pg mL−1a 7.96±4.58 8.21±2.91
MPO, ng mL−1b 24.91±13.68 32.80±21.59
P-selectin, ng mL−1b 53.55±36.52 34.46±14.69
sICAM-1, ng mL−1b 86.67±86.41 63.06±19.27
sVCAM-1, ng mL−1b 1088.00±882.80 870.10±116.60
SD, standard deviation.
aSerum analyte.
bPlasma analyte.
GM-CSF, granulocyte macrophage colony-stimulating factor; IFN-γ, interferon
gamma; IL, interleukin; MPO, myeloperoxidase; sICAM-1, soluble intercellular
adhesion molecule; sVCAM-1, soluble vascular cell adhesion molecule 1; TNF-α,
tumor necrosis factor alpha.
FIGURE 1 | Projection of participants onto the space spanned by the
first three latent variables (LVs) of the PLS-DA model. Red circles
correspond to normal walkers, blue squares identify slow walkers.
are also shown. The results of the PLS-DA classification model
were statistically significant, as for all of the three figures of merit,
p-values lower than 0.05 were obtained.
In order to identify the inflammatory markers, which were
mostly involved in discriminating between gait speed categories,
the values of the VIP indices were inspected. The variables cor-
responding to a VIP greater than 1 are reported in Table 3. Six
inflammatory markers were found to contribute significantly to
the discrimination model. The sign of the regression coefficients
of the PLS-DA model is reported to indicate how the concentra-
tion of each analyte varies between SW and NW groups. Since
the latter was coded as +1 in the dummy y vector, all biomark-
ers with positive regression coefficient had a higher concentration
in NWs relative to SWs, and vice versa. Accordingly, SWs were
characterized by higher circulating levels of IL8, myeloperoxi-
dase (MPO), and TNF-α, and lower levels of P-selectin, interferon
gamma (IFN-γ), and granulocyte macrophage colony-stimulating
factor (GM-CSF).
DISCUSSION
A large number of studies have explored the relationship between
inflammation and physical performance in older persons. Apart
from few exceptions, most reports relied on single mediators as
markers of the inflammatory state, with CRP, IL6, and TNF-αoften
playing the role of the “usual suspects” (14–18, 35, 36). However,
the inflammatory system is highly complex and involves several
cellular components of the innate (i.e., neutrophils, macrophages,
and mast cells) and adaptive (i.e., B and T lymphocytes) immune
response. The inflammatory network is modulated by a host
of mediators, such as chemokines, pro- and anti-inflammatory
cytokines, growth, and angiogenetic factors, and metabolic mark-
ers (e.g., adipokines), under reciprocal control through multiple
feedback mechanisms (37). Thus, focusing on single inflammatory
mediators may not be sufficient at capturing the intimate relation
linking inflammation and physical function in advanced age. This
complexity may also help explain the conflicting results reported
in the vast literature covering the topic (19).
In an attempt to address this issue, we built and validated a pre-
dictive classification model based on PLS-DA to characterize the
patterns of circulating inflammatory mediators associated with
different levels of physical performance. Our analysis unveiled
that older persons with a gait speed above the critical thresh-
old of 0.8 m s−1 were characterized by higher circulating levels of
P-selectin, IFN-γ, and GM-CSF. Conversely, higher levels of IL8,
MPO, and TNF-α defined the inflammatory profile of participants
walking slower than 0.8 m s−1.
Only sparse reports exist that assessed arrays of cytokines
in aging populations to determine, which combination of mea-
sures were best at predicting mortality, functional decay, or
other adverse health-related events (20–23). Using data from the
InCHIANTI (Invecchiare in Chianti; Aging in the Chianti Area)
study, Bandeen-Roche et al. (20) developed an index based on
seven circulating inflammatory markers (CRP, IL1β, IL1 recep-
tor antagonist, IL6, IL18, transforming growth factor beta 1,
and TNF-α), which was independently associated with wors-
ening mobility function and frailty risk. In the Health, Aging,
and Body Composition study, a multivariate statistical analy-
sis based on principal component analysis was conducted to
identify the “best” combination of inflammatory markers asso-
ciated with physical function (21). Two principal components
were identified, one related to TNF-α and the other to CRP,
which were associated with specific physical function measures.
In agreement with these reports, our findings support the idea
that distinct patterns of variation in inflammatory markers,
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FIGURE 2 | Distribution of (A) number of misclassifications (NMC), (B)
area under the ROC curve (AUROC), (C) and discriminant Q2 (DQ2 )
values under their respective null hypothesis as estimated by
permutation tests with 1,000 randomization (blue histograms) and
corresponding values obtained by the PLS-DA model on unpermuted
data (red dashed lines).
Table 3 | Inflammatory biomarkers mostly involved in the
discrimination between gait speed categories.
Inflammatory
marker
VIP Sign of regression
coefficient
P-selectin 3.37 +
IL8 1.73 −
IFN-γ 1.20 +
MPO 1.14 −
TNF-α 1.07 −
GM-CSF 1.04 +
VIP, variable importance in projection; GM-CSF, granulocyte macrophage colony-
stimulating factor; IFN-γ, interferon gamma; IL8, interleukin 8; MPO, myeloper-
oxidase; TNF-α, tumor necrosis factor alpha.
rather than a generalized elevation of single pro-inflammatory
mediators, are associated with functional outcomes in older
adults.
Although our study was not designed to address mechanistic
hypotheses, it can be speculated that the inflammatory profiles
characterizing NW and SW participants may reflect particular
aspects associated with innate immune system senescence. IL8
is a chemokine that targets polymorphonucleates (PMNs) and
promotes their adhesion, degranulation, respiratory burst, and
the synthesis of eicosanoids (38). TNF-α stimulates phagocyto-
sis, degranulation, and oxidative burst activity of PMNs, as well
as their migration through the endothelium via up-regulation of
endothelial adhesion molecules (39). Remarkably, IL8 and TNF-α
regulate the generation of each other (40, 41). Furthermore, the
exposure of neutrophils from healthy subjects to TNF-α and/or
IL8 enhanced free radical production through the activation of
NADPH oxidase and MPO (42).
The finding of higher circulating levels of IFN-γ and GM-
CSF in NW participants is in apparent contrast with the role
traditionally attributed to inflammation as a contributing factor
to the disabling process. However, recent evidence indicates that
the capacity to produce IFN-γ and GM-CSF upon stimulation is
positively associated with muscle mass and handgrip strength in
older men (43). Hence, the preservation of specific inflammatory
properties may protect against physical function deterioration in
late life, perhaps by acting in a hormetic-like fashion.
Further to this point, P-selectin emerged as the most important
inflammatory mediator in the discrimination between gait speed
categories, with higher levels found in NW elderly. Selectins are
adhesion molecules that mediate the initial rolling of leukocytes
along endothelial cells and activated platelets before their firm
adhesion and diapedesis at sites of tissue injury and inflammation
(44). Increased serum levels of P-selectin have been observed in
various cardiovascular disorders, indicating that this biomolecule
may serve as a marker for atherosclerosis and endothelial dysfunc-
tion (45). Nevertheless, the existence of a complex age-dependent
relation between circulating P-selectin levels and cardiovascular
disease has been reported (46). Indeed, individuals older than
65 years with documented coronary artery disease showed sig-
nificantly lower P-selectin levels than did healthy peers (46).
Hence, elevated serum levels of P-selectin may be beneficial in
some circumstances by preventing the inappropriate activation of
neutrophils in the circulation (47). Whether P-selectin exerts pro-
tective actions against physical function decline in advanced age,
as our data seem to suggest, deserves further investigation.
Although reporting novel findings, our study presents some
limitations that need to be acknowledged. First, analyses were con-
ducted in a relatively small group of subjects and involved a vast
array of experimental variables. However, the PLS-DA approach is
particularly suited for such experimental design because it allows
analyzing matrices in which (1) the number of variables is larger
than the number of individuals, (2) the variables are correlated
with each other, and (3) the differences in biological parame-
ters could be subtle and highly variable among the individuals
(34). Moreover, the double cross-validation procedure confirmed
the reliability of the PLS-DA model (32, 33). Since the pur-
pose of the investigation was to explore the relationship among
aging, inflammation, and functional status, the eligibility crite-
ria were quite restrictive. This approach does not allow extending
the results to severely ill, multimorbid subjects. In addition, the
study sample was mostly comprised of Caucasian individuals,
which impedes generalizing the findings to other ethnic groups.
Although only subjects not engaged in regular physical exercise
were enrolled, the amount of physical activity of participants was
not quantified. Hence, the relationship between inflammatory
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profiles and the overall level of physical activity could not be
established. The absence of longitudinal data on the panel of
inflammatory biomarkers obliged us to use a single time-point
measurement. No inference on the temporal relationship between
changes in inflammatory biomarkers and physical function decline
can therefore be drawn. Finally, although a fairly large number of
inflammatory biomolecules were assayed, we could obviously not
consider all known mediators. Notably, CRP was not measurable
with the multiplex assay kits chosen for the present study. Hence,
it cannot be excluded that more powerful predictors of physical
function might be obtained through the analysis of a larger range
of biomediators.
CONCLUDING REMARKS
Findings from the present study indicate that specific patterns of
circulating inflammatory markers characterize older persons with
different levels of physical performance, as estimated by gait speed.
The multivariate analytical strategy adopted allowed overcoming
the “one mediator fits all” paradigm (19) and identified robust
relationships between clusters of inflammatory biomolecules and
physical function levels. This initial investigation could, therefore,
pave the way for the identification of novel sets of biomarkers
related to physical performance in older individuals. This, in turn,
may provide new predictors of disability to be implemented in
the clinical arena and possible biological targets for preventive
interventions.
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